Kirk A. Staschke
Biochemistry, Genetics and Molecular Biology · Indiana University
Publications
263
Citations
3,206
Est. group size
~2
Recurring co-author estimate
Active years
33
Publishing since 1994
- Abstract 7032: The role of general control nonderepressible 2 (GCN2) kinase in leukemogenesis and therapeutic response to L-asparaginase
Cancer Research · 2025
- Abstract 1515: GCN2 eIF2 kinase promotes polyamine metabolism and progression of prostate cancer
Cancer Research · 2025
- PERK protein kinase facilitates keratinocyte collective cell migration by engagement with cell adhesion molecules, independent of its kinase activity
Molecular Biology of the Cell · 2025
- Abstract 1691 Differential Response of GCN2 eIF2 Kinase to Specific Amino Acid Limitations in Prostate Cancer
Journal of Biological Chemistry · 2024
- Abstract 388: Identifying synthetic lethalities in GCN2 KO tumors using an <i>in vivo</i> targeted CRISPRi screen
Cancer Research · 2024
- Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer
Science Signaling · 2024
- Abstract 4818: GCN2 eIF2 kinase and p53 coordinate amino acid homeostasis and metabolism in prostate cancer
Cancer Research · 2023
- Abstract 4240: Tumor PD-L1 induction associated with dietary protein restriction is modulated by PERK activation
Cancer Research · 2023
- GCN2 inhibition sensitizes prostate cancer cells to loss of p21 cell cycle control
Proceedings of IMPRS · 2023
- Abstract 4816: Targeting GCN2 regulation of amino acid homeostasis sensitizes prostate cancer cells to senolytic therapies
Cancer Research · 2023
- Abstract 4239: Alternate-day fasting enhances the activity of anti-androgen therapy in prostate cancer models
Cancer Research · 2023
- GCN2 is required to maintain core body temperature in mice during acute cold
American Journal of Physiology-Endocrinology and Metabolism · 2023
- A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
Clinical Cancer Research · 2023
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Clinical Cancer Research · 2023
- Abstract 6231: Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer models
Cancer Research · 2023
- Cancer Research×17
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Journal of Biological Chemistry×3
- Clinical Cancer Research×2
- The FASEB Journal×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile